Rising bacterial resistance to common antibiotics in Al Ain, United Arab emirates;Augmentation de la résistance bactérienne aux antibiotiques courants à Al Ain, (émirats arabes unis)

Eastern Mediterranean Health Journal

Volumn 17, Issue 6, 2011, Pages 479-484

  Al Kaabi, M R ^a   Tariq, W U Z ^a   Hassanein, A A ^a  

^a TAWAM HOSPITAL   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; NITROFURANTOIN; OXACILLIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; ESCHERICHIA COLI; KLEBSIELLA; NONHUMAN; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; TERTIARY HEALTH CARE; UNITED ARAB EMIRATES;

EID: 79959752403     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2011.17.6.479     Document Type: Article

References (16)

1. Okuma K et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. Journal of Clinical Microbiology, 2002, 40: 4289-4294.
2. Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science, 1992, 257: 1050-1055.
3. Abasaeed A et al. Self-medication with antibiotics by the community of Abu Dhabi Emirate, United Arab Emirates. Journal of Infection in Developing Countries, 2009, 3(7): 491-497.
4. Shibl A. The problem of antibiotic resistance. Arab Health Magazine, 2007, 12: 20-21.
5. Jumaa PA, Neringer R. A survey of antimicrobial resistance in a tertiary referral hospital in the United Arab Emirates. Journal of Chemotherapy (Florence, Italy), 2005, 17: 376-379.
6. Performance standards for antimicrobial susceptibility testing: nineteenth informational supplement M100-S19. Wayne, Pennsylvania, Clinical and Laboratory Standards Institute, 2009.
7. Parker MT, Hewitt JH. Methicillin resistance in Staphylococcus aureus. Lancet, 1970, 295: 800-804.
8. Donovan J. Antibiotic resistance in Australia. Health Issues No. 69, December 2001: 1-5.
9. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerging Infectious Diseases, 2007, 13: 1840-1846.
10. Jarvis WR. Prevention and control of methicillin-resistantStaphy-lococcus aureus: dealing with reality, resistance, and resistance to reality. Clinical Infectious Diseases, 2010, 50(2): 218-220.
11. Gootz TD, Marra A. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Review of Anti-Infective Therapy, 2008, 6: 309-325.
12. Silvia Munoz-Price LS, Weinstein RA. Acinetobacter infection. New England Journal of Medicine, 2008, 358: 1271-1281.
13. Johnson JR et al. Similarity between human and chicken Escherichia coli isolates in relation to ciprofloxacin resistance status. Journal of Infectious Diseases, 2006, 194: 71-78.
14. Johnson JR et al. Antimicrobial drug-resistant Escherichia coli from humans and poultry products, Minnesota and Wisconsin, 2002-2004. Emerging Infectious Diseases, 2007, 13: 838-846.
15. Sharma S, Bhat GK, Shenoy S. Virulence factors and drug resistance in Escherichia coli isolated from extraintestinal infections. Indian Journal of Medical Microbiology, 2007, 25: 369-373.
16. Hocquet D et al. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrobial Agents and Chemotherapy, 2007, 51: 3531-3536.